Ketoconazole enantiomer for the treatment of diabetes mellitus

  title={Ketoconazole enantiomer for the treatment of diabetes mellitus},
  author={R. Arakaki and B. Welles},
  journal={Expert Opinion on Investigational Drugs},
  pages={185 - 194}
  • R. Arakaki, B. Welles
  • Published 2010
  • Medicine
  • Expert Opinion on Investigational Drugs
  • The impact of hypercortisolism on multiple metabolic conditions is well recognized; the metabolic manifestations of Cushing's syndrome overlap with those seen in type 2 diabetes and the metabolic syndrome. Ketoconazole (KTZ), a widely used antifungal agent that inhibits various enzymes in adrenal cortisol synthesis, is effective in treating hypercortisolemia, but its use is limited by toxicities. KTZ is a racemic compound of two cis-enantiomers: (2R,4S)-(+)-KTZ and (2S,4R)-(-)-KTZ. The… CONTINUE READING
    15 Citations
    Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
    • 41
    • PDF
    Emerging drugs for Cushing’s disease
    • 13
    • PDF
    The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat
    • D. Hamdy, D. Brocks
    • Chemistry, Medicine
    • Xenobiotica; the fate of foreign compounds in biological systems
    • 2011
    • 10
    Diabetes Mellitus Secondary to Cushing’s Disease
    • 12
    • PDF
    Therapeutic compounds for Cushing’s syndrome: a patent review (2012-2016)
    • 4
    • Highly Influenced
    Enantiospecific Effects of Ketoconazole on Aryl Hydrocarbon Receptor
    • 23
    • PDF


    Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
    • 38
    11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
    • 25
    Modulation of glucocorticoid action and the treatment of type-2 diabetes.
    • 58
    Cortisol—cause and cure for metabolic syndrome?
    • B. Walker
    • Medicine
    • Diabetic medicine : a journal of the British Diabetic Association
    • 2006
    • 174